SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) for crofelemer powder for oral
Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for SBS-IF and microvillus inclusion disease (MVID) for crofelemer powder for oral solution, targeting a mid-2027
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternativesJaguar's rare disease intestinal failure development program for microvillus inclusion
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) for crofelemer powder for oral solution,
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives
SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc.
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing
Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026
Reverse split approved at April 2026 Special
Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease
Continuation of
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
